Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response | Zendy

Silvia Requena | Zendy; Ana Treviño | Zendy; Teresa Cabezas | Zendy; R. García-Delgado | Zendy; María José Amengual | Zendy; Ana Belén Peinado Lozano | Zendy; María Luz Pintos Peñaranda | Zendy; Juan Manuel Fernández | Zendy; Vincent Soriano | Zendy; Carmen de Mendoza | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response

Author(s) -

Silvia Requena,

Ana Treviño,

Teresa Cabezas,

R. García-Delgado,

María José Amengual,

Ana Belén Peinado Lozano,

María Luz Pintos Peñaranda,

Juan Manuel Fernández,

Vincent Soriano,

Carmen de Mendoza

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx090

Subject(s) - dolutegravir , raltegravir , integrase inhibitor , integrase , virology , medicine , drug resistance , human immunodeficiency virus (hiv) , viral load , antiretroviral therapy , genetics , biology

A broader extent of amino acid substitutions in the integrase of HIV-2 compared with HIV-1 might enable greater cross-resistance between raltegravir and dolutegravir in HIV-2 infection. Few studies have examined the virological response to dolutegravir in HIV-2 patients that failed raltegravir.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research